# Pemvidutide IMPACT: MASH and liver fibrosis at 24 weeks

Source: https://pepvault.app/research/pemvidutide-impact-2025

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Pemvidutide](https://pepvault.app/research#pemvidutide)

Randomized trial · people

# Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeks

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In this trial, pemvidutide cleared MASH in about half or more of patients within 24 weeks, but it did not yet improve liver scarring more than placebo.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 212
- **Published:** 2025
- **Journal:** Lancet

## What they tested

The team tested whether weekly pemvidutide clears MASH, a fatty liver disease with inflammation, or improves liver fibrosis (scarring) in people with stage F2 or F3 fibrosis.

## How the study was done

A randomized, double-blind, placebo-controlled phase 2b trial in 212 patients with biopsy-confirmed MASH and stage F2 or F3 fibrosis, at 83 sites in the USA and Australia. Patients got a weekly shot of pemvidutide 1.2 mg or 1.8 mg, with no step-up in dose, or placebo (a dummy shot), and these are the 24-week results of a 48-week trial that is still running.

<!--promo-->

PepVault for iPhone

## Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

At 24 weeks, MASH cleared without fibrosis getting worse in 24 of 41 patients (58%) in the 1.2 mg arm and 45 of 85 (52%) in the 1.8 mg arm, compared with 18 of 86 (20%) on placebo (p<0.0001 for both). Fibrosis improved by at least one stage without MASH getting worse in 33% and 36% of the two pemvidutide arms versus 28% on placebo, and these gaps were not statistically significant (p=0.59 and p=0.27). Side effects, mostly mild or moderate, were reported in 78% and 81% of the pemvidutide arms versus 67% on placebo. Stopping because of side effects was rare: none of the 41 patients on 1.2 mg, 1 of 85 on 1.8 mg and 2 of 86 on placebo.

## What it doesn’t show

These are 24-week results from an ongoing 48-week trial, and pemvidutide did not beat placebo on fibrosis improvement at this point. The trial was funded by Altimmune.

## The paper

Noureddin et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025.

- [PubMed (PMID 41237796)](https://pubmed.ncbi.nlm.nih.gov/41237796/)
- [The paper (DOI 10.1016/S0140-6736(25)02114-2)](https://doi.org/10.1016/S0140-6736%2825%2902114-2)
- [ClinicalTrials.gov (NCT05989711)](https://clinicaltrials.gov/study/NCT05989711)

## The compound

- [Pemvidutide: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/pemvidutide)
- [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)

## With this study

### Pemvidutide

- [Pemvidutide: the full reference](https://pepvault.app/peptides/pemvidutide)
- [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/pemvidutide-10mg)

### Studies

- [Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trial](https://pepvault.app/research/pemvidutide-impact-2026)
- [Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLD](https://pepvault.app/research/pemvidutide-browne-2025)
- [All 4 studies](https://pepvault.app/research#pemvidutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on Pemvidutide

- [Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trial](https://pepvault.app/research/pemvidutide-impact-2026) Randomized trial · people · 2026
- [Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLD](https://pepvault.app/research/pemvidutide-browne-2025) Randomized trial · people · 2025
- [Pemvidutide cut body weight about 25% in mice with NASH](https://pepvault.app/research/pemvidutide-nestor-2022) Animal study · mice · 2022
- [Every study on Pemvidutide](https://pepvault.app/research#pemvidutide)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Pemvidutide

- [Pemvidutide: the full reference](https://pepvault.app/peptides/pemvidutide)
- [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/pemvidutide-10mg)

### Studies

- [Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trial](https://pepvault.app/research/pemvidutide-impact-2026)
- [Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLD](https://pepvault.app/research/pemvidutide-browne-2025)
- [All 4 studies](https://pepvault.app/research#pemvidutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Pemvidutide](https://pepvault.app/research#pemvidutide)

## The library

- [Pemvidutide](https://pepvault.app/peptides/pemvidutide)
- [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
